Edwards Lifesciences Co. (NYSE:EW) Short Interest Update

Edwards Lifesciences Co. (NYSE:EW) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 11,310,000 shares, a growth of 54.9% from the December 15th total of 7,300,000 shares. Based on an average daily volume of 5,040,000 shares, the days-to-cover ratio is presently 2.2 days. Currently, 2.0% of the shares of the company are short sold.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,000 shares of company stock worth $2,195,180 over the last 90 days. 1.27% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Large investors have recently modified their holdings of the company. Harbor Capital Advisors Inc. raised its holdings in Edwards Lifesciences by 2.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after buying an additional 273 shares during the period. Nordea Investment Management AB lifted its holdings in shares of Edwards Lifesciences by 34.6% during the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after acquiring an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its position in Edwards Lifesciences by 6.7% during the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock worth $355,344,000 after purchasing an additional 300,000 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Edwards Lifesciences by 9.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock worth $31,571,000 after purchasing an additional 40,348 shares during the period. Finally, AIA Group Ltd increased its holdings in Edwards Lifesciences by 91.7% in the 3rd quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock valued at $49,461,000 after purchasing an additional 358,556 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of recent analyst reports. Wolfe Research cut shares of Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target on the stock. in a research note on Thursday. The Goldman Sachs Group increased their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Truist Financial restated a “hold” rating and issued a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Stifel Nicolaus raised their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. Finally, Citigroup boosted their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $78.48.

Edwards Lifesciences Trading Down 0.1 %

Shares of EW traded down $0.09 during mid-day trading on Friday, hitting $69.77. The company had a trading volume of 5,031,232 shares, compared to its average volume of 4,230,130. Edwards Lifesciences has a 1-year low of $58.93 and a 1-year high of $96.12. The business’s 50-day simple moving average is $71.99 and its 200-day simple moving average is $71.60. The stock has a market cap of $41.15 billion, a PE ratio of 10.07, a P/E/G ratio of 3.77 and a beta of 1.11. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.59 EPS. Sell-side analysts forecast that Edwards Lifesciences will post 2.56 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.